Leap Therapeutics, Inc. (NASDAQ:LPTX) announced its quarterly earnings data on Friday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by $0.03, Bloomberg Earnings reports.
Leap Therapeutics (NASDAQ LPTX) traded down 5.0202% on Friday, hitting $6.0977. 14,457 shares of the stock traded hands. The stock’s market capitalization is $57.27 million. Leap Therapeutics has a 12-month low of $5.40 and a 12-month high of $10.10. The company’s 50 day moving average price is $6.75 and its 200-day moving average price is $7.27.
Separately, Zacks Investment Research raised shares of Leap Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/12/leap-therapeutics-inc-nasdaqlptx-posts-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.